Shots:
- Chugai Pharmaceutical has entered into a joint research & license agreement with Gero to develop novel therapies for age-related diseases
- Chugai will develop novel antibody drugs using its proprietary antibody engineering techs for novel targets discovered by Gero’s AI target discovery platform, & obtain exclusive global rights to research, develop, manufacture, & commercialize antibodies arising from this partnership
- As per the deal, Gero will receive an undisclosed upfront & ~$250M in development or sales milestones, with net sales-based royalties
Ref: Globenewswire | Image: Chugai Pharmaceutical | Press Release
Related News:- Brii Biosciences Enters a Licensing Deal with Joincare Pharmaceutical for BRII-693 to Treat Bacterial Infections
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
